Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis

Exclusion Criteria

• •1. Uncontrollable local or systemic infections of the oral cavity and head and neck.
• •2. Active or history of autoimmune diseases; Diseases requiring systemic steroid hormones or immunosuppressive medications.
• •3. Bleeding occurred within 3 months before enrollment, including but not limited to: gastrointestinal bleeding caused by gastric fundus or esophageal varices, increased risk of bleeding caused by portal hypertension, active gastrointestinal bleeding, etc. Or there is a risk of major bleeding as assessed by the researcher.
• •4. Arterial/venous thrombosis that occurred within 6 months prior to the screening, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism, etc.
• •5. Interstitial pneumonia or active pneumonia with clinical significance, or other respiratory diseases that seriously affect lung function.
• •6. History of cardiovascular diseases, including but not limited to: (1) Congestive heart failure (NYHA grade \> 2); (2) Unstable angina pectoris; (3) Myocardial infarction occurred in the past three months; (4) Any supraventricular arrhythmia or ventricular arrhythmia that requires treatment or intervention.
• •7. Severe endocrine or hematopoietic system diseases (such as diabetes, leukemia, etc.), gastrointestinal obstruction, active bleeding, gastric perforation and other conditions.
• •8. Combined with malignant tumors of other organs.
• •9. Intractable or refractory epilepsy, with a large amount of pleural effusion, ascites, pericardial effusion, etc. that cannot be controlled by medicines.
• •10. History of HIV, syphilis, active hepatitis, active pulmonary tuberculosis, active EBV and/or CMV infection within one year before screening, or those with a history of active pulmonary tuberculosis infection for more than one year without regular treatment; active hepatitis B or C. Patients with positive HBsAg or HBcAb can participate in this study if the HBV DNA test is below the lower limit of the normal value detected by the research center; patients with positive HCV antibody can participate in this study if the HCV RNA test is below the lower limit of the normal value detected by the research center.
• •11. History of allogeneic bone marrow transplantation or solid organ transplantation.
• •12. Have received cell therapy products that have undergone genetic modification or editing in the past.
• •13. Have previously used medicines that can cause medication-related osteonecrosis of the jaw.
• •14. Have taken drugs containing taurine within one month before randomization in this study.
• •15. Allergic to taurine.
• •16. Patients who, in addition to radiotherapy, requires chemotherapy or immunotherapy simultaneously.
• •17. Mental illness, alcohol abuser, drug user or drug abuser.
• •18. Pregnant or lactating women; Women who plans to become pregnant within half a year after treatment.
• •19. Poor compliance or other circumstances assessed by the researcher as unsuitable for participation in this clinical study.